ArticleEye (London, England)2026
Application of platelet-rich fibrin membrane versus amniotic membrane graft transplantation after pterygium excision: a randomised clinical trial.
Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo compare the efficacy and safety of platelet-rich fibrin (PRF) membrane and amniotic membrane graft (AMG) transplantation in preventing recurrence after primary pterygium excision.
methodsThis prospective, single-blind, randomised clinical trial was conducted at Naresuan University Hospital. Eighty eyes with primary pterygium were randomly assigned to undergo either PRF membrane or AMG transplantation in a 1:1 ratio. Follow-up assessments were performed at 1 week, 1, 3, 6 and 12 months postoperatively. Outcomes included recurrence, surgical time, perioperative pain, complications, epithelialisation and the need for 5-fluorouracil (5-FU) injections. Recurrence was analysed using multilevel mixed-effects Poisson regression and Kaplan-Meier survival analysis.
resultsAt 12 months, recurrence occurred in 41.7% of PRF eyes and 28.2% of AMG eyes (P = 0.22), with no significant difference in recurrence-free survival (P = 0.16). Better cosmetic outcomes were observed in the AMG group (P = 0.004). Surgical time was comparable between groups (37.2 vs 36.8 min; P = 0.81), while perioperative pain was higher in the PRF group (4.0 ± 1.9 vs 2.5 ± 2.1; P = 0.001). Complication rates and epithelialisation were similar between groups (P = 1.00 and P = 0.50, respectively). The PRF group required more 5-FU injections than the AMG group (80% vs 42.5%; P < 0.001).
conclusionsPRF membrane grafting results in comparable recurrence and complication rates to AMG transplantation and is advantageous because of its simple preparation and autologous nature. However, the patients in PRF group had less favourable cosmetic outcomes.
Identifiers
42521759What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.